| |
| |
|
| Insider
Information: |
Leonhardt Harry J |
| Relationship: |
|
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
329,950 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,431,718 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
329,950 |
|
|
| Total
Value |
$3,431,718 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Senomyx Inc |
SNMX |
SVP, Gen.Counsel & Cor... |
2007-09-04 |
48,937 |
|
0 |
Premium* |
|
|
Amylin Pharmaceuticals Inc |
AMLN |
SVP, Legal, Compl & Co... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
SVP, GC |
2019-04-13 |
66,373 |
2016-04-13 |
0 |
Premium* |
|
|
Poseida Therapeutics, Inc. |
PSTX |
|
2024-03-01 |
214,640 |
2022-03-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
58 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
92,772 |
148,526 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2023-03-01 |
4 |
D |
$5.35 |
$23,128 |
D/D |
(4,323) |
144,203 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2024-03-01 |
4 |
D |
$4.13 |
$67,344 |
D/D |
(16,306) |
214,640 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,743 |
230,946 |
0 |
- |
|
| SNMX |
Senomyx Inc |
SVP Gen Counsel & Corp Scty |
• – – |
2007-02-15 |
4 |
AS |
$12.73 |
$19,097 |
D/D |
(1,500) |
65,437 |
0 |
- |
|
| SNMX |
Senomyx Inc |
SVP Gen Counsel & Corp Scty |
• – – |
2007-04-16 |
4 |
AS |
$13.08 |
$62,152 |
D/D |
(4,752) |
62,437 |
0 |
- |
|
| SNMX |
Senomyx Inc |
SVP Gen Counsel & Corp Sec |
• – – |
2006-06-15 |
4 |
AS |
$12.65 |
$12,650 |
D/D |
(1,000) |
78,391 |
|
- |
|
| SNMX |
Senomyx Inc |
SVP Gen Counsel & Corp Sectry |
• – – |
2006-07-17 |
4 |
AS |
$13.11 |
$13,107 |
D/D |
(1,000) |
77,391 |
|
- |
|
| SNMX |
Senomyx Inc |
SVP Gen Counsel & Corp Secty |
• – – |
2006-09-15 |
4 |
AS |
$15.04 |
$37,603 |
D/D |
(2,500) |
72,937 |
0 |
- |
|
| SNMX |
Senomyx Inc |
SVP Gen. Counsel & Corp Sec. |
• – – |
2006-02-15 |
4 |
AS |
$15.50 |
$147,569 |
D/D |
(9,520) |
83,391 |
|
- |
|
| SNMX |
Senomyx Inc |
SVP Gen. Counsel & Corp Sec. |
• – – |
2006-05-15 |
4 |
AS |
$12.78 |
$12,777 |
D/D |
(1,000) |
79,391 |
|
- |
|
| SNMX |
Senomyx Inc |
SVP Gen. Counsel & Corp Secty |
• – – |
2006-08-15 |
4 |
AS |
$13.41 |
$13,406 |
D/D |
(1,000) |
76,391 |
|
- |
|
| SNMX |
Senomyx Inc |
SVP Gen. Counsel & Corp Secty |
• – – |
2006-09-01 |
4 |
AS |
$14.96 |
$14,272 |
D/D |
(954) |
75,437 |
|
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,413 |
54,971 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-03 |
4 |
D |
$16.12 |
$91,207 |
D/D |
(5,658) |
49,313 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-14 |
4 |
D |
$16.54 |
$44,658 |
D/D |
(2,700) |
54,422 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,809 |
57,122 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-22 |
4 |
D |
$16.81 |
$66,215 |
D/D |
(3,939) |
61,875 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,392 |
65,814 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-04-13 |
4 |
D |
$16.54 |
$39,316 |
D/D |
(2,377) |
66,373 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
68,750 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2016-04-13 |
4 |
D |
$11.76 |
$30,376 |
D/D |
(2,583) |
4,292 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2016-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
6,875 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2017-02-03 |
4 |
D |
$12.26 |
$75,987 |
D/D |
(6,198) |
13,507 |
0 |
- |
|
58 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
